SMT201500295B - Procedimento per la riduzione della pressione intraoculare negli umani - Google Patents

Procedimento per la riduzione della pressione intraoculare negli umani

Info

Publication number
SMT201500295B
SMT201500295B SM201500295T SM201500295T SMT201500295B SM T201500295 B SMT201500295 B SM T201500295B SM 201500295 T SM201500295 T SM 201500295T SM 201500295 T SM201500295 T SM 201500295T SM T201500295 B SMT201500295 B SM T201500295B
Authority
SM
San Marino
Prior art keywords
humans
procedure
intraocular pressure
reducing intraocular
reducing
Prior art date
Application number
SM201500295T
Other languages
English (en)
Italian (it)
Inventor
Shikha Barman
Rudolf A Baumgartner
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500295(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of SMT201500295B publication Critical patent/SMT201500295B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
SM201500295T 2009-05-01 2015-11-30 Procedimento per la riduzione della pressione intraoculare negli umani SMT201500295B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17465509P 2009-05-01 2009-05-01
US21999009P 2009-06-24 2009-06-24
PCT/US2010/033112 WO2010127210A1 (en) 2009-05-01 2010-04-30 Method of reducing intraocular pressure in humans

Publications (1)

Publication Number Publication Date
SMT201500295B true SMT201500295B (it) 2016-01-08

Family

ID=43030847

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500295T SMT201500295B (it) 2009-05-01 2015-11-30 Procedimento per la riduzione della pressione intraoculare negli umani

Country Status (25)

Country Link
US (2) US8470800B2 (enExample)
EP (1) EP2424546B1 (enExample)
JP (1) JP5778663B2 (enExample)
KR (1) KR101757940B1 (enExample)
CN (1) CN102413832B (enExample)
AU (1) AU2010242943B2 (enExample)
BR (1) BRPI1009971A2 (enExample)
CA (1) CA2762064A1 (enExample)
CL (1) CL2011002675A1 (enExample)
DK (1) DK2424546T3 (enExample)
EA (1) EA024042B1 (enExample)
ES (1) ES2554684T3 (enExample)
HR (1) HRP20151200T1 (enExample)
HU (1) HUE028068T2 (enExample)
IL (1) IL216081A (enExample)
MX (1) MX2011011229A (enExample)
MY (1) MY159244A (enExample)
NZ (1) NZ596428A (enExample)
PL (1) PL2424546T3 (enExample)
PT (1) PT2424546E (enExample)
RS (1) RS54378B1 (enExample)
SG (1) SG175346A1 (enExample)
SI (1) SI2424546T1 (enExample)
SM (1) SMT201500295B (enExample)
WO (1) WO2010127210A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
MX2012004225A (es) * 2009-10-26 2012-06-08 Inotek Pharmaceuticals Corp Formulacion oftalmica y metodo de fabricacion de la misma.
AU2011203897B2 (en) * 2010-01-11 2016-11-17 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
ME02594B (me) 2010-03-19 2017-06-20 Inotek Pharmaceuticals Corp Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska
ES2613254T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular
BR112012023749A2 (pt) 2010-03-26 2016-08-23 Inotek Pharmaceuticals Corp método para reduzir a pressão intraocular em humanos utilizando n6-ciclopentiladenosina (cpa), derivados de cpa ou pró-fármacos desses
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
BR112014018413A8 (pt) * 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
EA201591433A1 (ru) 2013-03-15 2015-12-30 Инотек Фармасьютикалс Корпорейшн Офтальмологические составы
CA2967446A1 (en) * 2014-12-03 2016-06-09 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
EP1962597A4 (en) * 2005-11-30 2008-12-17 Inotek Pharmaceuticals Corp PURINE DERIVATIVES AND METHOD OF USE
MX2012004225A (es) * 2009-10-26 2012-06-08 Inotek Pharmaceuticals Corp Formulacion oftalmica y metodo de fabricacion de la misma.
AU2011203897B2 (en) * 2010-01-11 2016-11-17 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
ME02594B (me) * 2010-03-19 2017-06-20 Inotek Pharmaceuticals Corp Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska
ES2613254T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular

Also Published As

Publication number Publication date
KR20120017026A (ko) 2012-02-27
KR101757940B1 (ko) 2017-07-13
JP2012525437A (ja) 2012-10-22
MY159244A (en) 2016-12-30
CL2011002675A1 (es) 2012-06-01
SG175346A1 (en) 2011-11-28
EA201171339A1 (ru) 2012-05-30
CN102413832A (zh) 2012-04-11
EA024042B1 (ru) 2016-08-31
AU2010242943B2 (en) 2016-09-29
NZ596428A (en) 2014-03-28
PL2424546T3 (pl) 2016-04-29
US20130217643A1 (en) 2013-08-22
DK2424546T3 (en) 2015-12-14
JP5778663B2 (ja) 2015-09-16
HRP20151200T1 (hr) 2016-01-15
RS54378B1 (sr) 2016-04-28
CA2762064A1 (en) 2010-11-04
ES2554684T3 (es) 2015-12-22
EP2424546B1 (en) 2015-10-28
PT2424546E (pt) 2015-12-23
BRPI1009971A2 (pt) 2016-03-15
IL216081A0 (en) 2012-01-31
WO2010127210A1 (en) 2010-11-04
US20100279970A1 (en) 2010-11-04
EP2424546A1 (en) 2012-03-07
SI2424546T1 (sl) 2016-02-29
US8470800B2 (en) 2013-06-25
HUE028068T2 (en) 2016-11-28
CN102413832B (zh) 2015-11-25
HK1167599A1 (en) 2012-12-07
EP2424546A4 (en) 2013-01-23
AU2010242943A1 (en) 2011-12-01
IL216081A (en) 2015-11-30
MX2011011229A (es) 2011-11-18

Similar Documents

Publication Publication Date Title
SMT201500295B (it) Procedimento per la riduzione della pressione intraoculare negli umani
EP2496182A4 (en) FLAP GRAFT
EP2393547A4 (en) RETINAL PROSTHESIS
EP2513299A4 (en) ADIPEOUS FABRIC DECELLULARIZED
EP2475287A4 (en) Child chair
EP2476885A4 (en) INTERNAL PRESSURE REGULATOR
DK2437762T3 (da) Kunstige tårer og terapeutiske anvendelser
BRPI1015403A2 (pt) válvula
EP2424476A4 (en) RETINA GRAFT
DK2401441T3 (da) Udluftningsventil
DE112010004770A5 (de) Rückschlagventil
DE112010002724A5 (de) Membranventil
EP2460523A4 (en) TABLET
SMT201700017B (it) Combinazione, kit e metodo per ridurre la pressione intraoculare
EP2767261C0 (en) Inflatable Penile Implant
BRPI1009887A2 (pt) unidade de válvula
EP2416228A4 (en) DECOMPRESSION VALVE
IT1397669B1 (it) Dispositivo di valvola del gas
EP2297527A4 (en) PRESSURE VALVE
DK2425134T3 (da) Kompressorventilarrangement
GB0911272D0 (en) Surgical evacuation valve
DK2255112T3 (da) Minimumtrykventil
EP2481416A4 (en) EYE DROP
FR2946083B1 (fr) Turbine basse-pression
EP2297526A4 (en) PRESSURE VALVE